IDEAS home Printed from https://ideas.repec.org/a/nwe/natrud/y2022i4p57-65.html
   My bibliography  Save this article

Reporting of R&D Costs Under IAS 38 – The Case of Biopharmaceutical Companies

Author

Listed:
  • Maria Markova

    (University of National and World Economy, Sofia, Bulgaria)

  • Georgi Hristov

    (University of National and World Economy, Sofia, Bulgaria)

Abstract

The objective of the paper is to provide insights into the effects of IAS 38 on the financial information provided by companies operating in the biopharmaceutical industry, taking into account the increased expenditure on research and development activities during the COVID-19 pandemic. Financial reports for 2019 and 2020 of BioNTech SE (the company responsible for the development of one of the authorized COVID-19 vaccines) are analysed and given as an example for how the capitalization and expensing of R&D costs affect the information provided by entities. Example for improvement of the R&D accounting treatment is presented in the case of IFRS 6 “Exploration for and Evaluation of Mineral Resources†.

Suggested Citation

  • Maria Markova & Georgi Hristov, 2022. "Reporting of R&D Costs Under IAS 38 – The Case of Biopharmaceutical Companies," Nauchni trudove, University of National and World Economy, Sofia, Bulgaria, issue 4, pages 57-65, November.
    • Handle: RePEc:nwe:natrud:y:2022:i:4:p:57-65
    as

    Download full text from publisher

    File URL: https://unwe-research-papers.org/bg/journalissues/article/10549
    Download Restriction: no
    ---><---

    More about this item

    Keywords

    research and development costs; intangible assets; biopharmaceutical industry; COVID-19 vaccines; accounting policy;
    All these keywords.

    JEL classification:

    • M41 - Business Administration and Business Economics; Marketing; Accounting; Personnel Economics - - Accounting - - - Accounting

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nwe:natrud:y:2022:i:4:p:57-65. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Vanya Lazarova (email available below). General contact details of provider: https://edirc.repec.org/data/unweebg.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.